Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Core Viewpoint - Nyxoah SA will release its financial results for the fourth quarter and full year of 2025 on March 19, 2026, and will host a conference call to discuss these results [1]. Company Overview - Nyxoah is a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA) through neuromodulation [4]. - The company's lead product is the Genio system, which is a leadless and battery-free hypoglossal neurostimulation therapy for OSA, a condition linked to increased mortality risk and cardiovascular issues [4]. Recent Developments - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [5]. - Nyxoah has completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021 [5]. - The company received CE mark approval for expanding therapeutic indications to Complete Concentric Collapse (CCC) patients after positive outcomes from the BETTER SLEEP study [5]. - Nyxoah announced positive results from the DREAM IDE pivotal study and received FDA approval for a subset of adult patients with moderate to severe OSA [5]. Financial Communication - A conference call will take place on March 19, 2026, at 10:30 PM CET / 4:30 PM ET to discuss the financial results [1]. - The call will be accessible via the Investor Relations page of Nyxoah's website [2]. - For those wishing to ask questions, registration is required, and an email will be sent with dial-in details and a unique access code [3]. Additional Information - The archived webcast of the call will be available for replay shortly after the call concludes [3]. - For more information about Nyxoah and its products, the company encourages visiting its website [6].